The invention relates to an NK3 agonist or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of an atrial arrhythmia. The invention further relates to a composition comprising an NK3 agonist for use in the treatment of a patient suffering from a disease wherein the electrical activity of an atrial heart cell is affected.